BRCA1/2胚系突变对三阴性乳腺癌患者放疗后第二原发肿瘤的影响

胡晓钰, 蔡毓文, 叶富贵, 邵志敏, 胡伟刚, 余科达

  1. 1.复旦大学附属肿瘤医院放疗科,复旦大学上海医学院肿瘤学系,上海 200032
    2.复旦大学附属肿瘤医院乳腺外科,复旦大学上海医学院肿瘤学系,上海 200032
  • 收稿日期:2023-10-24 修回日期:2024-02-18 出版日期:2024-02-29 发布日期:2024-03-14
  • 通信作者: 余科达
  • 作者简介:胡晓钰(ORCID: 0009-0002-4596-6629),本科,技师。

摘要/Abstract

摘要:

背景与目的:乳腺癌易感基因1/2(BRCA1/2)的编码产物在维持机体基因组稳定性方面发挥着重要的作用。BRCA1/2致病突变是否会导致机体对放射线的脆弱度增加,从而诱发第二原发肿瘤尚不清楚。本文旨在探讨BRCA1/2基因胚系突变的三阴性乳腺癌患者术后接受放射治疗是否是增加罹患第二原发肿瘤的危险因素。方法:基于复旦大学附属肿瘤医院2007年1月1日—2014年12月31日收集的回顾性三阴性乳腺癌队列(292例为BRCA1/2突变的女性三阴性乳腺癌患者),针对其开展分析,分别在非BRCA1/2胚系突变患者(n = 261)与BRCA1/2胚系突变患者(n = 31)中进行多元logistic回归分析,以评估影响第二原发肿瘤的风险因素,并对上述两人群中的分析结果进行交互作用分析,从而评估BRCA1/2胚系突变与放疗的交互作用。本研究除特殊说明外,均采用双侧检验且检验水准α = 0.05。本研究所有样本的获得与使用均得到了复旦大学附属肿瘤医院伦理委员会的批准(050432-4-2108),且每个患者均提供了书面知情同意。结果:BRCA1/2胚系突变患者中进行多元logistic回归分析提示术后接受放疗相对于未接受放疗显著增加了第二原发肿瘤的风险[比值比(odds ratio,OR) = 2.479,95% CI:1.971 ~ 3.118,P<0.001)。而在非BRCA1/2胚系突变患者中,放疗对第二原发肿瘤的效应则不显著。BRCA1/2胚系突变与放疗对于第二原发肿瘤的发生无显著的交互作用(OR = 9.71,95% CI:0.32 ~ 295.25,P = 0.193)。结论:虽然统计学分析结果显示,与未接受放疗的患者相比,BRCA1/2胚系突变的患者术后放疗会增加罹患第二原发肿瘤的风险,但BRCA1/2胚系突变与放疗对第二原发肿瘤的发生并无相互交叉作用,因而BRCA1/2胚系突变患者术后接受放疗可能并不会增加罹患第二原发肿瘤的风险。

关键词: 乳腺癌, BRCA1, BRCA2, 放疗, 第二原发肿瘤

Abstract:

Background and purpose: BRCA1/2 plays an important role in maintaining the genome stability. Whether BRCA1/2 germline mutation could increase the tumor sensitivity to radiotherapy, thereby inducing secondary primary cancer after radiotherapy is unclear. This study aimed to investigate whether postoperative radiotherapy is a risk factor for the development of second primary cancer in triple-negative breast cancer (TNBC) patients with BRCA1/2 germline mutation. Methods: This research was based on a previously reported retrospective cohort, i.e., the Fudan University Shanghai Cancer Center TNBC cohort. Between January 1, 2007 and December 31, 2014, a total of 292 female TNBC patients with BRCA1/2 mutation were enrolled. We performed logistic regression analysis in patients without BRCA1/2 germline mutation (n=261) and BRCA1/2 germline mutation patients (n=31), respectively, to assess the risk factors affecting the incidence of second primary cancer. We then performed interactive analysis on the above two analyses to evaluate the interactive effect between BRCA1/2 germline mutation and postoperative radiotherapy. P<0.05 indicates a statistically significant difference. The research was approved by Fudan University Shanghai Cancer Center TNBC Ethics Committee (050432-4-2108), and each patient provided written informed consent. Results: Logistic regression analysis in patients with BRCA1/2 germline mutations showed that postoperative radiotherapy significantly increased the risk of secondary primary disease compared to non-radiotherapy [odds ratio (OR)=2.475, 95% confidence interval (CI): 1.933-3.167, P<0.001]. In patients without BRCA1/2 germline mutation, the effect of radiotherapy on the incidence of second primary tumor was not significant. There was a significant interaction between BRCA1/2 germline mutation and postoperative radiotherapy for the incidence of secondary primary cancer (OR=9.710, 95% CI: 0.320-295.250, P=0.193). Conclusion: Although statistical analysis results show that patients with BRCA1/2 germline mutations have an increased risk of developing a second primary tumor after postoperative radiotherapy compared to patients who have not received radiotherapy, there is no significant correlation between BRCA1/2 germline mutations and radiotherapy for the development of a second primary tumor. Therefore, patients with BRCA1/2 germline mutations who receive radiotherapy after surgery may not increase the risk of developing a second primary tumor.

Key words: Breast cancer, BRCA1, BRCA2, Radiotherapy, Second primary cancer

中图分类号: 

相关文章

[1] 张琪, 修秉虬, 吴炅. 2023年中国乳腺癌重要临床研究成果及最新进展[J]. 中国癌症杂志, 2024, 34(2): 135-142.
[2] 张思源, 江泽飞. 2023年改变晚期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2024, 34(2): 143-150.
[3] 王昭卜, 黎星, 于鑫淼, 金锋. 2023年改变早期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2024, 34(2): 151-160.
[4] 罗扬, 孙涛, 邵志敏, 崔久嵬, 潘跃银, 张清媛, 程颖, 李惠平, 杨燕, 叶长生, 于国华, 王京芬, 刘运江, 刘新兰, 周宇红, 柏玉举, 谷元廷, 王晓稼, 徐兵河, 宋礼华. AK-HER2与参照药治疗HER2阳性转移性乳腺癌患者的疗效、体内代谢特征、安全性和免疫原性比较:一项多中心、随机、双盲Ⅲ期等效性临床试验[J]. 中国癌症杂志, 2024, 34(2): 161-175.
[5] 陈远香, 余涛, 杨诗雨, 曾涛, 魏兰, 张彦. KDM4A通过下调BMP9促进乳腺癌细胞MDA-MB-231的迁移和侵袭[J]. 中国癌症杂志, 2024, 34(2): 176-184.
[6] 杨彦举, 方应涛, 高大地, 王佳舟, 赵俊, 胡伟刚. uRT-TPS和Monaco-TPS对同一直线加速器在多癌种放射剂量计算方面差异的比较[J]. 中国癌症杂志, 2024, 34(1): 82-89.
[7] 金奕滋, 林明曦, 张剑. 乳腺癌原发灶与肝转移灶受体表达差异研究[J]. 中国癌症杂志, 2023, 33(9): 834-843.
[8] 杨忠毅, 许晓平, 王明伟, 张勇平, 杨建伟, 陈跃, 徐文贵, 李亚明, 章英剑, 宋少莉. 乳腺癌18F-FES雌激素受体PET技术和应用标准[J]. 中国癌症杂志, 2023, 33(8): 801-808.
[9] 王若曦, 吉芃, 龚悦, 陈盛. HER2低表达乳腺癌新辅助化疗效果及其预后特征:一项单中心回顾性研究[J]. 中国癌症杂志, 2023, 33(7): 686-692.
[10] 王雁, 苏越, 胡涂, 刘绮颖, 姚伟强, 陈勇, 严望军, 章真. 33例接受术前放疗的局部高危软组织肉瘤患者近期疗效和安全性回顾性分析[J]. 中国癌症杂志, 2023, 33(7): 693-700.
[11] 邬思雨, 李俊杰, 邵志敏. 乳腺癌前哨淋巴结活检术的发展历史及研究进展[J]. 中国癌症杂志, 2023, 33(6): 551-559.
[12] 毕钊, 王永胜. 1~2枚前哨淋巴结阳性早期乳腺癌患者治疗策略降阶梯新理念[J]. 中国癌症杂志, 2023, 33(6): 560-565.
[13] 赵谦, 凌云霄, 柳光宇. 乳腺癌患者保乳手术后再次前哨淋巴结活检的最新研究进展及展望[J]. 中国癌症杂志, 2023, 33(6): 566-573.
[14] 丛斌斌, 曹晓珊, 王春建, 邱鹏飞, 孙晓, 陈鹏, 刘雁冰, 赵桐, 张朝蓬, 石志强, 毕钊, 王永胜. 临床查体阴性但超声检查及穿刺确诊腋窝淋巴结转移的乳腺癌前哨淋巴结活检的可行性分析[J]. 中国癌症杂志, 2023, 33(6): 574-580.
[15] 任恒宇, 郝爽, 陈嘉健, 杨犇龙, 曹阿勇, 柳光宇, 邵志敏, 吴炅. 国内外乳房重建研究的现状和重点:一项文献计量学研究[J]. 中国癌症杂志, 2023, 33(6): 581-588.